Sudarshan Pharma Industries (543828) Q2 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the half year ended 30th September 2024 were approved and released, with limited review by statutory auditors confirming no material misstatements.

Financial highlights

• Standalone revenue from operations for H1 FY25 was ₹22,535.02 lakhs, down from ₹23,376.31 lakhs in H2 FY24, and net profit was ₹591.86 lakhs, compared to ₹646.04 lakhs in the previous half year.

• Consolidated revenue from operations for H1 FY25 was ₹22,779.09 lakhs, with net profit at ₹592.33 lakhs, compared to ₹660.29 lakhs in H2 FY24.

• Basic and diluted EPS for H1 FY25 stood at ₹2.46 (standalone and consolidated), compared to ₹2.68 (standalone) and ₹2.74 (consolidated) in H2 FY24.

Outlook and guidance

• Management confirmed continued focus on specialty chemicals and pharmaceutical manufacturing, with recent acquisitions and subsidiary formation to expand product offerings and market reach.